The FDA has proposed cutting fees for early-stage companies conducting clinical development in the U.S. instead of abroad. | ...

A new chemical method that could speed up the creation of medicines, materials and products people rely on every day has been ...

Excelsior Sciences said on Wednesday it has raised $95 million to develop technology that uses machines and artificial ...

This year has seen the approval of several first-in-class therapies for HAE, but in a fragmented space, experts question ...

In a university lab, an AI system generated millions of novel molecules to fight drug-resistant infections. And they're ...

In a Q&A, Recursion’s incoming CEO acknowledges hype around the idea of using AI to expedite drug development, and says it's ...

FDA proposals include ‘major updates’ to simplify biosimilarity studies, reduce unnecessary clinical testing, and ease the ...

Phase 1 results show that SUL-238 is safe, well-tolerated, and demonstrates favorable pharmacokinetics with high CSF ...

Simulations Plus' silico software boosts non-animal drug development and drives growth. Read here for an investment analysis ...

The FDA plans to begin requiring one clinical study, instead of the standard two, for medical products before consideration ...

The U.S. Food and Drug Administration is moving Theresa Michele, longtime director of the office of non-prescription drugs, ...